Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Product Categories
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.
C18 Ceramide is an endogenous bioactive sphingolipid. It is the primary short-chain ceramide found in brain tissue whose synthesis is regulated by longevity-assurance homologue 1 (Lass1) in mice.1 Increased expression of C18 ceramide reduces cell growth in UM-SCC-22A squamous cell carcinoma cells.2 It is selectively downregulated in 32 human head and neck squamous cell carcinoma tumor tissues as compared to non-squamous tumor tissues. C18 Ceramide concentration is significantly higher in muscle tissue of type 2 diabetic patients compared with non-diabetic patients and is positively correlated to body mass index and inversely related to insulin sensitivity.3 [Matreya, LLC. Catalog No. 1832]
WARNING This product is not for human or veterinary use.
1. Mammalian Lass6 and its related family members regulate synthesis of specific ceramides. Biochem J. 390(Pt. 1), 263-271 (2005).
2. Defects in cell growth regulation by C18:0-
3. Muscle sphingolipids during rest and exercise: A C18:0 signature for insulin resistance in humans. Diabetologia 59(3), 785-791 (2016).